Methyl-coenzyme M Reductase (MCR) Receptor as Potential Drug Target for Inhibiting Methanogenesis in Horses Using Moringa oleifera L.: An in Silico Docking Study.

This study investigates the potential use of compounds from the Moringa oleifera plant to inhibit the production of methane in horses. The research uses software modelling to suggest that Tetradecanoic acid, a compound in the plant, may be particularly effective.

Methane Emission in Livestock

• Methane emission, particularly from nonruminant livestock such as horses, is a significant problem for veterinarians and the environment globally.
• Reducing these emissions by inhibiting the production of methane (methanogenesis) in these animals could have important environmental benefits.

Research Overview

• The researchers employed in silico (computer simulation) methods to analyse the potential antimethanogenic properties of phytocomponents (plant compounds) related to Moringa oleifera L. against the methyl-coenzyme M reductase (MCR) receptor in horses.
• The pharmacokinetics and ADME (absorption, distribution, metabolism, and excretion) attributes of these compounds were initially determined using Lipinski’s rule of five and the Swiss ADME tool.
• The five compounds that showed potential drug-like qualities with no violation were 3,5-bis(1,1-dimethylethyl)-phenol, Kaempferol, Moringine, Niazimisin, and Tetradecanoic acid.

Molecular Docking Analysis

• This research stage involved using Hex 8.0.0 docking software to perform a molecular docking analysis – predicting how the chosen molecules and the MCR receptor in horses would interact.
• The results revealed that Tetradecanoic acid showed the highest binding energy against the receptor with an E-value of -142.98 KJ/mol.
• The other compounds yielded lower binding energies: Niazimisin (-133.98 KJ/mol), Kaempferol (-110.36 KJ/mol), 3,5-bis(1,1-dimethylethyl)-phenol (-93.72 KJ/mol), and Moringyne (-92.62 KJ/mol).

Conclusions and Implications

• These findings suggest that Tetradecanoic acid could potentially be harnessed as a substantial antimethanogenic agent to create efficient methane-reducing drugs by blocking the process of methanogenesis.
• Furthermore, these in silico results might considerably decrease the financial costs associated with performing in vivo (within living organisms) studies, propelling the future development of antimethanogenic drugs for horses.